MedTrace Logo

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

NCT05609812 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2025-05-23

No results posted yet for this study

Summary

The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.

Conditions

  • Lupus Nephritis (LN)

Interventions

DRUG

Atacicept

Once weekly subcutaneous (SC) injections by prefilled syringe

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Vera Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Joanne Curley · Chief Development Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-02
Primary Completion
2026-03-15
Completion
2028-12-15
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05609812 on ClinicalTrials.gov